RecruitingNCT05763641
TAD After Chemotherapy in Locally Advanced Breast Cancer
Target Axillary Dissection After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
Sponsor
Hospital Universitari de Bellvitge
Enrollment
162 participants
Start Date
Feb 1, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Axillary lymph node metastasis proven by cytology
- Clinical or radiological N2a (at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis)
- Extensive T4 subsidiary to axillary lymphadenectomy according to current clinical criteria
- Neoadjuvant chemotherapy
Exclusion Criteria5
- cN3 verified by imaging tests
- N2 due to internal mammary involvement (N2b).
- Tumors whose surrogate molecular subtype is luminal A.
- Patients undergoing neoadjuvant endocrine therapy
- Patients with local recurrences and metastatic tumors.
Interventions
PROCEDURETarget Axillary Dissection
TAD after neoadjuvant chemotherapy and subsequent axillary lymph node dissection
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05763641
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location